HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer

Files in This Item:
LC74-2_248-252.pdf302.19 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/47868

Title: Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer
Authors: Sakakibara-Konishi, Jun Browse this author →KAKEN DB
Oizumi, Satoshi Browse this author →KAKEN DB
Kinoshita, Ichiro Browse this author →KAKEN DB
Shinagawa, Naofumi Browse this author →KAKEN DB
Kikuchi, Junko Browse this author
Kato, Mototsugu Browse this author →KAKEN DB
Inoue, Tetsuya Browse this author →KAKEN DB
Katoh, Norio Browse this author →KAKEN DB
Onimaru, Rikiya Browse this author →KAKEN DB
Shirato, Hiroki Browse this author →KAKEN DB
Dosaka-Akita, Hirotoshi Browse this author →KAKEN DB
Nishimura, Masaharu Browse this author →KAKEN DB
Keywords: Phase I study
Non-small cell lung cancer
Chemotherapy
Paclitaxel
Carboplatin
Radiation
Issue Date: Nov-2011
Publisher: Elsevier Ireland
Journal Title: Lung Cancer
Volume: 74
Issue: 2
Start Page: 248
End Page: 252
Publisher DOI: 10.1016/j.lungcan.2011.02.009
PMID: 21397973
Abstract: Introduction: Although paclitaxel with carboplatin and thoracic radiotherapy has improved survival for patients with locally advanced unresectable non-small cell lung cancer (NSCLC), the optimal dose of paclitaxel has not been well defined in Japan. This study was conducted to determine the maximum tolerated dose (MTD) and recommended dose (RD) of paclitaxel in combination with carboplatin and concurrent real-time tumor-tracking thoracic radiation therapy (thoracic RTRT). Patients and methods: Previously untreated patients with histologically confirmed, locally advanced unresectable NSCLC were eligible. Before treatment, gold markers were inserted into the lung and the mediastinum of all patients. RTRT comprised a total of 66 Gy at 2 Gy/fraction, 5 days/week, for 7 weeks. Patients received paclitaxel at a starting dose of 40 mg/m2 followed by carboplatin at a fixed area under the curve (AUC) of 2, as a weekly regimen with RTRT. The dose of paclitaxel was escalated by 5 mg/m2 per level. Results: Eight patients with locally advanced unresectable NSCLC were enrolled and treated with two dose levels of paclitaxel (40 mg/m2 and 45 mg/m2), carboplatin (AUC = 2) and RTRT. No dose limiting toxicities (DLTs) were observed at Level 1 (paclitaxel, 40 mg/m2 and carboplatin, AUC = 2). At Level 2 (paclitaxel, 45 mg/m2 and carboplatin, AUC = 2), two of five patients experienced DLTs, in the form of esophagitis and discontinuation of chemotherapy more than twice. The MTD and RD of paclitaxel were thus defined as 45 mg/m2 and 40 mg/m2, respectively. Conclusions: This phase I study was well tolerated and the RD of paclitaxel and carboplatin with RTRT is 40 mg/m2 at AUC = 2, respectively. Further studies are warranted to evaluate the efficacy of this regimen.
Type: article (author version)
URI: http://hdl.handle.net/2115/47868
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 大泉 聡史

Export metadata:

OAI-PMH ( junii2 , jpcoar )


 

Feedback - Hokkaido University